A retrospective analysis of Sorafenib treatment with and without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma (HCC) With Main Portal Vein Tumor Thrombosis (MPVTT).

Trial Profile

A retrospective analysis of Sorafenib treatment with and without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma (HCC) With Main Portal Vein Tumor Thrombosis (MPVTT).

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top